IP Library Granted Patent US 7,947,483
Granted Patent B2
US 7,947,483 · App. 11/891,602 · Granted May 24, 2011

Methods and organisms for the growth-coupled production of 1,4-butanediol

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,947,483
App. No.
11/891,602
Granted
May 24, 2011
Kind
B2
Abstract

The invention provides a non-naturally occurring microorganism comprising one or more gene disruptions, the one or more gene disruptions occurring in genes encoding an enzyme obligatory to coupling 1,4-butanediol production to growth of the microorganism when the gene disruption reduces an activity of the enzyme, whereby the one or more gene disruptions confers stable growth-coupled production of 1,4-butanediol onto the non-naturally occurring microorganism. The microorganism can further comprise a gene encoding an enzyme in a 1,4-butanediol (BDO) biosynthetic pathway. The invention additionally relates to methods of using microorganisms to produce BDO.

Claims (14)

1. A non-naturally occurring Escherichia coli microorganism comprising a set of metabolic modifications, said set of metabolic modifications comprising disruption of genes encoding alcohol dehydrogenase, pyruvate formate lyase, lactate dehydrogenase and malate dehydrogenase, wherein said E. coli microorganism expresses heterologous enzymes that provide production of 1,4-butanediol.

2. The non-naturally occurring E. coli microorganism of claim 1 , said gene disruptions further comprising aspartate transaminase.

3. The non-naturally occurring E. coli microorganism of claim 1 , wherein one or more of said gene disruptions comprise a deletion of one or more of said genes.

4. The non-naturally occurring E. coli microorganism of claim 3 , wherein each of said gene disruptions comprise a deletion.

5. The non-naturally occurring E. coli microorganism of claim 2 , wherein one or more of said gene disruptions comprise a deletion of one or more of said genes.

6. The non-naturally occurring E. coli microorganism of claim 5 , wherein each of said gene disruptions comprise a deletion.

7. A method of producing 1,4-butanediol, comprising:

(a) culturing the non-naturally occurring E. coli microorganism of claim 1 ; and

(b) isolating 1,4-butanediol produced from said non-naturally occurring E. coli microorganism.

8. The method of claim 7 , said gene disruptions further comprising aspartate transaminase.

9. The method of claim 7 , wherein one or more of said gene disruptions comprise a deletion of one or more of said genes.

10. The method of claim 9 , wherein each of said gene disruptions comprise a deletion.

11. The method of claim 8 , wherein one or more of said gene disruptions comprise a deletion of one or more of said genes.

12. The method of claim 11 , wherein each of said gene disruptions comprise a deletion.

Assignments (3)
SECURITY INTEREST Recorded Feb 10, 2026
From: GENOMATICA, INC.
To: AGAIN BIO APS
Reel/Frame 074708/0001 →
SECURITY INTEREST Recorded Dec 9, 2025
From: GENOMATICA, INC.
To: NOVO HOLDINGS A/S, AS COLLATERAL AGENT
Reel/Frame 073915/0027 →
SECURITY INTEREST Recorded Jun 2, 2025
From: GENOMATICA, INC.
To: OXFORD FINANCE LLC
Reel/Frame 071471/0770 →